Non-Small Cell Lung Cancer

Preliminary Diagnosis: Non-Small Cell Lung Cancer

I. What imaging technique is first-line for this diagnosis?

  • CT of the chest with intravenous contrast

II. Describe the advantages and disadvantages of this technique for diagnosis of non-small cell lung cancer.


  • Can adequately assess the T stage of the tumor

  • Useful for identifying pleural nodules, pleural plaques, pleural/pericardial effusions, or metastasis

  • CT should include the upper abdomen to assess for adrenal metastasis

  • Easily accessible at most medical facilities

  • Better tolerated in obese or claustrophobic patients


  • Low sensitivity (40-84%) and specificity (57-94%) for identifying mediastinal and lymph node involvement

  • Positive predictive value (PPV) of 50% and negative predictive value (NPV) of 85%

  • Limited in detecting chest wall or parietal pleural invasion

  • Limited in detecting extra-thoracic metastatic disease

  • Requires the use of IV contrast

  • Exposure to ionizing radiation

III. What are the contraindications for the first-line imaging technique?

  • Contraindicated in pregnant patients, especially during the first and second trimester

  • Contraindicated in patients with iodine allergies

  • It should be used with caution in patients with acute renal insufficiency.

IV. What alternative imaging techniques are available?

  • PET/CT (commonly used as adjunct to chest CT for full staging)

  • MRI of chest

  • Chest X-ray

V. Describe the advantages and disadvantages of the alternative techniques for non-small cell lung cancer.



  • Delineates anatomy and also determines metabolic activity of suspicious lesions

  • Improved sensitivity (98%) versus CT alone at identifying mediastinal invasion and lymph node metastases

  • Improved sensitivity and specificity for detecting extrathoracic metastatic disease versus CT alone

  • Can help determine locations for highest-yield biopsy, especially if considering invasive mediastinal lymph node staging

  • Helpful when planning definitive courses of radiation and determining disease response to treatment

  • Can drastically alter management by upstaging patients, making them inoperable, thus eliminating unnecessary surgery


  • Expensive and not easily accessible at certain medical centers

  • High false positive rate (20%), which may require pathologic confirmation to rule out.

  • PET scans alone (without CT hybrid) are not as sensitive in detecting mediastinal or extrathoracic metastases and often more difficult to elucidate anatomy

MRI of chest/abdomen/brain with IV contrast


  • Can help better assess extrathoracic and chest wall invasion

  • Does not expose patient to ionizing radiation

  • Can help delineate brain, adrenal, or spinal metastases


  • Loss of signal from physiologic lung movement

  • Not as well tolerated in obese, claustrophobic, or patients with SOB or not able to hold breath

  • More time consuming than CT

Chest X-ray


  • Cheap, easily accessible, easy to administer

  • Requires lower dose of radiation exposure

  • Helpful in comparing with previous films to determine if further workup is necessary


  • Unable to determine full staging

  • Insufficient to assess mediastinal and lymph node metastases

  • Cannot determine extrathoracic metastases

VI. What are the contraindications for the alternative imaging techniques?


  • Because CT is a component of this imaging technique, it is contraindicated in pregnant women.


  • Contraindicated in patients with pacemakers and other implantable, MRI-incompatible devices

  • Since contrast is administered, caution should be used in patients with renal insufficiency


  • There are no major contraindications for this imaging modality.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs